Traws Pharma (TRAW) Proxy Filing summary

Executive summary

• Special Meeting will seek approval for four key proposals: conversion of Series C Preferred Stock, increase in authorized shares, reverse stock split, and potential adjournment to solicit more votes.

• The Board unanimously recommends voting in favor of all proposals, citing strategic benefits and improved financial flexibility.

• The merger with Trawsfynydd Therapeutics, Inc. was completed on April 1, 2024, with a concurrent $15 million financing to support clinical development.

• H.C. Wainwright & Co. provided a fairness opinion, concluding the exchange ratio in the merger is fair from a financial perspective.

• The company will focus on four clinical-stage compounds, two from the merger and two legacy assets.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of common stock upon conversion of Series C Preferred Stock, subject to Nasdaq rules.

• Proposal 2: Approve amendment to increase authorized common shares from 125M to 250M.

• Proposal 3: Approve reverse stock split at a ratio between 1-for-15 and 1-for-25, at Board's discretion.

• Proposal 4: Approve adjournment of the meeting if more time is needed to solicit votes.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Post-merger, the Board consists of seven members: four designated by the company, three by Trawsfynydd.

• Werner Cautreels serves as CEO and director; other key officers include Iain Dukes (Executive Chairman) and Mark Guerin (CFO).

• Directors and officers are indemnified for six years post-merger, with continued D&O insurance.